AR043062A1 - Ureas sustituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer - Google Patents

Ureas sustituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR043062A1
AR043062A1 ARP030104378A ARP030104378A AR043062A1 AR 043062 A1 AR043062 A1 AR 043062A1 AR P030104378 A ARP030104378 A AR P030104378A AR P030104378 A ARP030104378 A AR P030104378A AR 043062 A1 AR043062 A1 AR 043062A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
optionally substituted
alkoxy
Prior art date
Application number
ARP030104378A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32469374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of AR043062A1 publication Critical patent/AR043062A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

Los compuestos son útiles para el tratamiento de la enfermedad de Alzheimer y otras enfermedades similares. Los compuestos incluyen inhibidores de la enzima beta-secretasa que son útiles para el tratamiento de la enfermedad de Alzheimer y otras enfermedades caracterizadas por el depósito de péptido A beta en un mamífero. Los compuestos de la invención son útiles en composiciones farmacéuticas y métodos de tratamiento para reducir la formación de péptido A beta. Reivindicación 1: Un compuesto de la fórmula (1) o sales o ésteres farmacéuticamente aceptable de los mismos; en donde X está ausente -(C=O)-, -(C=S)-, -S(O)n1- o -(C=N-Z), en donde Z=R20 o -OR20, y en donde n1 es 0, 1 o 2; T está ausente, NR20, u O, con la condición de que cuando X es -(C=O), T no está ausente; en donde cada R20 es en forma independiente H, -CN, alquilo o alquenilo, haloalquilo C1-6 o cicloalquilo C4-7, con la condición de que cuando Z es R20 o -OR20, R20 no es -CN; en donde R1 es -(CH2)1-2-S(O)0-2-(alquilo C1-6), o alquilo C1-10 substituido en forma opcional con 1, 2, o 3 grupos seleccionados en forma independiente de halógeno, -OH, -O, -SH, -C:::N, -CF3, -alcoxi C1-3, amino, mono- o dialquilamino, -N(R)C(O)R'-, -OC(=O)-amino y -OC(=O)-mono- o dialquilamino, o alquenilo C2-6 o alquinilo C2-6, cada uno de los cuales está substituido en forma opcional con 1, 2, o 3 grupos seleccionados en forma independiente de halógeno, -OH, -SH, -C:::N, -CF3, alcoxi, amino, y mono- o dialquilamino, o arilo, heteroarilo, heterociclilo, -alquil C1-6-arilo, -alquil C1-6-heteroarilo, o -alquil C1-6-heterociclilo, donde las porciones de anillo de cada uno son substituidas en forma opcional con 1, 2, 3, o 4 grupos seleccionados en forma independiente de halógeno, -OH, -SH, -C:::N, -NR105R'105, -CO2R, -N(R)COR', o -N(R)SO2R', -C(=O)-alquilo C1-4, -SO2-amino, -SO2-mono o dialquilamino, -C(=O)-amino, -C(=O)-mono o dialquilamino, -SO2-alquilo C1-4, o alcoxi C1-6 substituido en forma opcional con 1, 2, o 3 grupos which are seleccionados en forma independiente de halógeno, o cicloalquilo C3-7 substituido en forma opcional con 1, 2, o 3 grupos seleccionados en forma independiente de halógeno, -OH, -SH, -C:::N, -CF3, alcoxi C1-3, amino, -alquilo C1-6 y mono- o dialquilamino, o alquilo C1-10 substituido en forma opcional con 1, 2, o 3 grupos seleccionados en forma independiente de halógeno, -OH, -SH, -C:::N, -CF3, -alcoxi C1-3, amino, mono- o dialquilamino y -alquilo C1-3, o alquenilo C2-10 o alquinilo C2-10 cada uno de los cuales es substituido en forma opcional con 1, 2, o 3 grupos seleccionados en forma independiente de halógeno, -OH, -SH, -C:::N, -CF3, alcoxi C1-3, amino, alquilo C1-6 y mono- o dialquilamino; y el grupo heterociclilo es además opcionalmente substituido con oxo; R y R' son en forma independiente hidrógeno, alquilo C1-10, alquilarilo C1-10 o alquilheteroarilo C1-10; en donde Rc es (I) -[-(CH2)(0-8)-(CH)(alquil1) (alquil2)], donde alquil1 y alquil2 son lineales o ramificados alcanilo C2-10, alquenilo o alquinilo, y en donde alquil1 y alquil2 se unen al mismo o diferente carbono de metileno con las valencias de metileno que permanecen abiertas ocupadas por hidrógeno, formando de dicho modo una cadena alquilo ramificada de entre 8 y 20 átomos de carbono en total; los grupos alquilo, alquil1 y alquil2 son substituidos en forma opcional con uno, dos o tres substituyentes seleccionados de un grupo compuesto por alquilo, halógeno, -OH, -SH, -C:::N, -CF3, alcoxi, -O-fenilo, -C(O)alquilo C1-3, -NR1-aR1-b donde R1-a y R1-b son -H o alquilo C1-6, -OC=ONR1-aR1-b, -S(=O)0-2, -NR1-aC=O NR1-aR1-b, -C=ONR1-aR1-b, y -S(=O)2NR1-aR1-b; (II) -(C(Rc-x)(Rc-y))(0-4)-Rc-ciclo en donde cada Rc-x y Rc-y es en forma independiente seleccionado entre H, C1 -C6 alquilo C1-6, C1 -C6 alcoxi C1-6, alquenilo C2-6 o alquinilo -(CH2)0-4-Rc-ciclo donde Rc-ciclo es tal como se lo define debajo y Rc-x y Rc-y pueden tomarse juntos con el carbono del metileno al cual se unen en forma conjunta para formar un anillo espirocíclico de 3 a 7 átomos compuestos por carbono y hasta 2 de O, S(O)(0-2) y NRa', en donde Ra' es H o alquilo C1-4; en donde el anillo espirocíclico puede fusionarse con otro anillo a fin de brindar un sistema de anillo bicíclico compuesto por carbono y hasta 2 de O, S(O)(0-2) y NRa'. y comprendiendo hasta 9 átomos en total, incluyendo, Rc-ciclo es cualquier anillo arilo, heteroarilo, o cicloalquilo o un sistema de anillos fusionado que consiste en no más de tres anillos, donde cada uno es igual o diferente y es un anillo arilo, heteroarilo, o cicloalquilo en donde Rc-ciclo es substituido en forma opcional con hasta cuatro substituyentes seleccionados en forma independiente de: (1) alquilo C1-6 substituido en forma opcional con uno dos o tres substituyentes seleccionados del grupo compuesto por alquilo C1-3, halógeno, -OH, -SH, -C:::N, -CF3, alcoxi C1-3, y -NR1-aR1-b, (2) alquenilo C2-6 o alquinilo con una o dos uniones no saturadas, substituido en forma opcional con uno, dos o tres substituyentes seleccionados del grupo compuesto por -F, -Cl, -OH, -SH, -C:::N, -CF3, alcoxi C1-3, y -NR1-aR1-b, (3) halógeno, (4) alcoxi C1-6, (5) -alcoxi C1-6 substituido en forma opcional con uno, dos, o tres de -F, (6) -NRN-6RN-7 donde RN-6 y RN-7 son iguales o diferentes y se seleccionan de un grupo compuesto por: (a) -H, (b) -alquilo C1-6 substituido en forma opcional con un substituyente seleccionado de un grupo compuesto por: (i) -OH, y (ii) -NH2, (c) -alquilo C1-6 substituido en forma opcional con uno a tres -F, -Cl, -Br, o -I, (d) -cicloalquilo C3-7, (e) -(alquil C1-2)-(cicloalquilo C3-7), (f) -(alquil C1-6)-O-(alquilo C1-3), (g) -alquenilo C2-6 con una o dos uniones dobles, (h) -alquinilo C2-6 con uno o dos uniones triples, (i) cadena -alquilo C1-6 con una unión doble y una unión triple, (j) -R1-arilo donde R1-arilo es tal como se lo describe precedentemente, y (k) -R1-heteroarilo donde R1-heteroarilo es tal como se lo describe precedentemente, (7) -OH, (8) -C:::N, (9) cicloalquilo C3-7, substituido en forma opcional con uno, dos o tres substituyentes seleccionados del grupo compuesto por -F, -Cl, -OH, -SH, -C:::N, -CF3, alcoxi C1-3, y -NR1-aR1-b, (10) -CO-(alquilo C1-4), (11) -SO2-NR1-aR1-b, (12) -CO-NR1-aR1-b, (13) -SO2-(alquilo C1-4), y cuando existe un átomo de carbono saturado en Rc-ciclo (14) oxo, (15) oxima (16) anillos quetales de 5 a 7 miembros, y (17) un anillo espirocíclico compuesto por 3 a 7 átomos que comprenden carbono y cuando el tamano del anillo es de 4-7 átomos opcionalmente hasta 2 de O, S(O)(0-2) y NRa'. (IV) -(CRc-xRc-y)0-4-heteroarilo, (III) -(CRc-xRc-y)0-4-aril-arilo (IV) -(CRc-xRc-y)0-4-aril-heteroarilo, (V) -(CRc-xRc-y)0-4-heteroaril-arilo, (VI) -(CRc-xRc-y)0-4-heteroaril-heteroarilo, (VII) -(CRc-xRc-y)0-4-aril-heterociclo, (VIII) -(CRc-xRc-y)0-4-heteroaril-heterociclo, (IX) -(CRc-xRc-y)0-4-heterociclo-arilo, (X) -(CRc-xRc-y)0-4-heterociclo-heteroarilo, (XI) -(CRc-xRc-y)0-4-heterociclo-heterociclo, (XII) -[C(Rc-1)(Rc-2)]1-3-[CO]0-1-N-(Rc-3)2 donde cada Rc-1 es igual o diferente y es seleccionado de un grupo compuesto por: H, alquilo C1-4 y alcoxi C1-4 y donde cada Rc-2 y Rc-3 es en forma independiente seleccionado de (A) -alquilo C1-6, substituido en forma opcional con uno, dos o tres substituyentes seleccionados del grupo compuesto por alquilo C1-3, -F, -Cl, -Br, -I, -OH, -SH, -C:::N, -CF3, alcoxi C1-6, -O- fenilo, y -NR1-aR1-b, (B) alquenilo C2-6 o alquinilo con una o dos uniones no saturadas, substituido en forma opcional con uno, dos o tres substituyentes seleccionados del grupo compuesto por alquilo C1-3, -F, -Cl, -Br, -I, -OH, -SH, -C:::N, -CF3, alcoxi C1-6, -O-fenilo, y -NR1-aR1-b, (C) -(CH2)1-2-S(O)0-2-(alquilo C1-6) (D) -(CH2)0-4-cicloalquilo C3-7 substituido en forma opcional con uno, dos o tres substituyentes seleccionados del grupo compuesto por alquilo C1-3, -F, -Cl, -Br, -I, -OH, -SH, -C:::N, -CF3, alcoxi C1-6, -O- fenilo, -NR1-aR1-b, (E) -(CH2)0-4-heterociclo de 5-7 miembros substituido en forma opcional con uno, dos o tres substituyentes seleccionados del grupo compuesto por alquilo C1-3, -F, -Cl, -Br, -I, -OH, -SH, -C:::N, -CF3, alcoxi C1-6, -O-fenilo, oxo, -NR1-aR1-b, (XIII) -CH(arilo)2 donde cada arilo es igual o diferente, (XIV) -CH(heteroarilo)2 donde cada heteroarilo es igual o diferente y son tal como se los define precedentemente, (XVIII) -CH(arilo)(heteroarilo), en donde RN is R'100, -(CRR')1-6R'100, -(CRR')0-6R100, -(CRR')1-6-O-R'100, -(CRR')1-6-S-R'100, -(CRR')1-6-C(=O)-R100, -(CRR')1-6SO2-R100, -(CRR')1-6-NR100-R'100 o -SO2R'100, con la condición de que cuando RN es -SO2R'100, X no es -S(=O)n- o -C(=S)-; en donde R100 y R'100 representan en forma independiente arilo, heteroarilo, -aril-W-arilo, -aril-W-heteroarilo, -aril-W-heterociclilo, -heteroaril-W-arilo, -heteroaril-W-heteroarilo, -heteroaril-W-heterociclilo, -heterociclil-W-arilo, -heterociclil-W-heteroarilo, -heterociclil-W-heterociclilo, -CH [(CH2)0-2-O-R150]-(CH2)0-2-arilo, -CH [(CH2)0-2-O-R150]-(CH2)0-2-heterociclilo o -CH[(CH2)0-2-O-R150]-(CH2)0-2-heteroarilo, donde las porciones de anillos de cada uno son substituidas en forma opcional con 1, 2, o 3 grupos seleccionados en forma independiente de -OR, -NO2, halógeno, -C:::N, -OCF3, -CF3, -(CH2)0-4-O-P(=O)(OR)(OR'), -(CH2)0-4-CO-NR105R'105, -(CH2)0-4-O-(CH2)0-4-CONR102R102', -(CH2)0-4-CO-(alquilo C1-12), -(CH2)0-4-CO-(alquenilo C2-12), -(CH2)0-4-CO-(alquinilo C2-12), -(CH2)0-4-CO-(CH2)0-4 (cicloalquilo C3-7), -(CH2)0-4-R110, -(CH2)0-4-R120, -(CH2)0-4-R130, -(CH2)0-4-CO-R110, -(CH2)0-4-CO-R120, -(CH2)0-4-CO-R130, -(CH2)0-4-CO-R140, -(CH2)0-4-CO-O-R150, -(CH2)0-4-SO2-NR105R'105, -(CH2)0-4-SO-(alquilo C1-8), -(CH2)0-4-SO2 (alquilo C1-12), -(CH2)0-4-SO2-(CH2)0-4-(cicloalquilo C3-7), -(CH2)0-4-N(R150)-CO-O-R150, -(CH2)0-4-N(R150)-CO-N(R150)2, -(CH2)0-4-N(R150)-CS-N(R150)2, -(CH2)0-4-N(R150)-CO-R105, -(CH2)0-4-NR105R'105, -(CH2)0-4-R140, -(CH2)0-4-O-CO-(alquilo), -(CH2)0-4-O-P(O)-(O-R110)2, -(CH2)0-4-O-CO-N(R150)2, -(CH2)0-4-O
ARP030104378A 2002-11-27 2003-11-27 Ureas sustituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer AR043062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42976902P 2002-11-27 2002-11-27

Publications (1)

Publication Number Publication Date
AR043062A1 true AR043062A1 (es) 2005-07-13

Family

ID=32469374

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104378A AR043062A1 (es) 2002-11-27 2003-11-27 Ureas sustituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer

Country Status (14)

Country Link
US (2) US7351738B2 (es)
EP (1) EP1565428A1 (es)
JP (1) JP2006508166A (es)
AR (1) AR043062A1 (es)
AU (1) AU2003293155A1 (es)
BR (1) BR0316629A (es)
CA (1) CA2507484A1 (es)
DO (1) DOP2003000765A (es)
MX (1) MXPA05005649A (es)
PA (1) PA8589701A1 (es)
PE (1) PE20040762A1 (es)
TW (1) TW200505828A (es)
UY (1) UY28101A1 (es)
WO (1) WO2004050609A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7291744B2 (en) * 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20060014790A1 (en) * 2004-01-21 2006-01-19 Varghese John Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
CA2558249A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
CA2572775A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1797052A1 (en) * 2004-09-17 2007-06-20 Comentis, Inc. Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
BRPI0608581A2 (pt) * 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
KR20080015079A (ko) * 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
EP1912963B1 (en) * 2005-08-03 2011-10-12 Merck Sharp & Dohme Corp. Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
US7816387B2 (en) * 2005-09-05 2010-10-19 Dainippon Sumitomo Pharma Co., Ltd. β secretase inhibitor
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
CA2624904A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
WO2007061670A1 (en) * 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
WO2008147547A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
EP2167471B1 (en) 2007-05-25 2013-10-16 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
JP2010534683A (ja) * 2007-07-26 2010-11-11 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害するイソフタルアミド誘導体
JP2011518188A (ja) 2008-04-18 2011-06-23 ユニバーシティ オブ コネチカット リソソーム調節のための化合物および使用方法
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6133152A (ja) * 1984-06-22 1986-02-17 アボツト　ラボラトリ−ズ リ−ニン阻害化合物
EP0190891A3 (en) * 1985-01-31 1988-04-20 Kissei Pharmaceutical Co. Ltd. Novel amino acid derivatives
US4665055A (en) * 1985-06-17 1987-05-12 Merck & Co., Inc. Peptide renin inhibitors
US5175281A (en) 1985-09-12 1992-12-29 The Upjohn Company Pharmaceutically active pyrimidinylpiperazinylsterioids
CA1297631C (en) * 1985-12-23 1992-03-17 Sesha I. Natarajan Ureido renin inhibitors
US4864017A (en) 1986-09-05 1989-09-05 The Upjohn Company Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
JPH06505963A (ja) * 1990-11-19 1994-07-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
DK0971033T3 (da) * 1991-01-21 2009-12-14 Elan Pharm Inc Test og model til Alzheimers sygdom
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9203836A (es) * 1991-07-02 1993-01-01 Sandoz Ag Derivados de acido-4-amino-3-hidroxicarboxilico y proceso para su preparacion.
PT620849E (pt) * 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
DK0656888T3 (da) * 1992-08-25 1998-02-09 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfonamider, anvendelige som retrovirale protease-inhibitorer
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
EP1001019A1 (en) * 1993-10-27 2000-05-17 Athena Neurosciences, Inc. Transgenic animals harboring APP Allele having Swedish mutation
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
ATE201197T1 (de) * 1994-07-07 2001-06-15 Pharmeco Lab Inc Diarinopropanole abgeleitet von aminosäuren
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
WO1996040885A2 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH09124629A (ja) * 1995-10-26 1997-05-13 Kissei Pharmaceut Co Ltd カルバミン酸テトラヒドロフリルエステル誘導体の製造方法
JP2001503643A (ja) 1996-11-20 2001-03-21 オクラホマ メディカル リサーチ ファウンデーション アスパラギン酸プロテアーゼの一種であるナプシンのクローニングおよび特徴付け
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
CA2343004A1 (en) 1998-09-24 2000-03-30 Pharmacia & Upjohn Company Alzheimer's disease secretase
EP1165609A2 (en) 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Human beta-secretase enzyme, inhibitors and their compositions and uses
ES2254156T3 (es) * 1999-02-12 2006-06-16 Vertex Pharmaceuticals Incorporated Inhibidores de aspartil-proteasa.
CA2376420A1 (en) 1999-06-15 2000-12-21 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
PE20010693A1 (es) 1999-09-23 2001-06-24 Upjohn Co Metodo para la determinacion de actividad alfa-secretasa sobre la app
GB0012795D0 (en) * 2000-05-25 2000-07-19 Novartis Ag Organic compounds
WO2002002505A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US6696488B2 (en) * 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
ES2307764T3 (es) * 2001-06-01 2008-12-01 Elan Pharmaceuticals, Inc. Derivados de hidroxialquilaminas como inhibidores de la beta-secretasa y su uso para el tratamiento de la enfermedad de alzheimer y enfermedades similares.
IL159808A0 (en) * 2001-07-11 2004-06-20 Elan Pharm Inc N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
MXPA04005428A (es) * 2001-12-06 2004-12-06 Elan Pharm Inc Hidroxietilaminas substituidas.
JP2005519082A (ja) * 2002-02-27 2005-06-30 イーラン ファーマスーティカルズ、インコーポレイテッド 置換されているヒドロキシエチルアミン
ATE367394T1 (de) * 2002-04-26 2007-08-15 Gilead Sciences Inc Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
DE60315664D1 (de) * 2002-06-20 2007-09-27 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
BR0314071A (pt) * 2002-09-06 2005-07-05 Pharmacia & Upjohn Co Llc Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US7291744B2 (en) * 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
US20040209925A1 (en) 2004-10-21
US20080306136A1 (en) 2008-12-11
BR0316629A (pt) 2005-10-11
CA2507484A1 (en) 2004-06-17
TW200505828A (en) 2005-02-16
JP2006508166A (ja) 2006-03-09
WO2004050609A1 (en) 2004-06-17
MXPA05005649A (es) 2005-08-16
PE20040762A1 (es) 2004-11-06
EP1565428A1 (en) 2005-08-24
US7351738B2 (en) 2008-04-01
PA8589701A1 (es) 2004-11-26
AU2003293155A1 (en) 2004-06-23
UY28101A1 (es) 2004-06-30
WO2004050609A8 (en) 2005-07-21
DOP2003000765A (es) 2004-05-31
AU2003293155A8 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
AR043062A1 (es) Ureas sustituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR063165A1 (es) Derivados de acido boronico como inhibidores de amidihidrolasa de acidos grasos. composiciones farmaceuticas.
AR047682A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
AR013085A1 (es) Compuestos derivados de macrolidos c-4'' sustituidos, composicion farmaceutica, metodo de preparacion, compuestos intermediarios para su preparacion
AR044514A1 (es) Acidos carboxilicos alfa sustituidos como moduladores ppar
AR041997A1 (es) Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR035612A1 (es) 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa
AR050433A1 (es) Derivados piperidilo de quinazolina e isoquinolina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR032353A1 (es) Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR070728A1 (es) Derivados de pirazolo[1,5-a]pirimidina, composicion farmaceutica que los comprende y metodo para hacer el compuesto, asociable con la inhibicion de la actividad raf quinasa en un mamifero
AR046326A1 (es) Compuestos de heteroarilo de 6-miembros para el tratamiento de trastornos neurodegenerativos
AR016715A1 (es) Compuestos antibioticos macrolidos 3,6-cetal y enol eter, composiciones farmaceuticas, metodo para tratar una infeccion, metodo para tratar el cancer yprocedimiento de preparacion
AR044006A1 (es) Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
PE20232051A1 (es) Compuestos carboxi-benzimidazol moduladores de glp-1r
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR045999A1 (es) Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal